Cargando…

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients

OBJECTIVE: To explore the efficacy and safety of intermittent, oral famciclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. METHOD: We retrospectively analyzed the incidence of bortezomib treatment-related varicella-zoster virus reactivation in 719 newly-diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Gaofeng, Guan, Fangshu, Han, Xiaoyan, Yang, Li, Zhao, Yi, Yang, Yang, Zhang, Enfang, He, Jingsong, He, Donghua, Wu, Wenjun, Huang, He, Cai, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965704/ https://www.ncbi.nlm.nih.gov/pubmed/35372089 http://dx.doi.org/10.3389/fonc.2022.843032

Ejemplares similares

Efficacy of valacyclovir and famciclovir in herpes zoster: A comparative study
por: Bist, Ankita, et al.
Publicado: (2020)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
por: Yang, Li, et al.
Publicado: (2018)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

A review of famciclovir in the management of genital herpes.
por: Faro, S
Publicado: (1998)

The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma
por: Yi, Yang-Seon, et al.
Publicado: (2010)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis
por: He, Donghua, et al.
Publicado: (2021)

Herpes zoster complicating bortezomib therapy
por: Sahu, Kamal Kant, et al.
Publicado: (2015)

Famciclovir (FAMVIR(®))
por: Sacks, Stephen L.
Publicado: (1997)

Comparison of a One- versus Two-Week Treatment with Famciclovir Upon Reductions in Pain and Occurrence of Postherpetic Neuralgia in Herpes Zoster: A Randomized Open-Label Trial
por: Peng, Fen, et al.
Publicado: (2023)

Herpes zoster duplex bilateralis in bortezomib-based chemotherapy
por: Onaka, Takashi, et al.
Publicado: (2016)

Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
por: Lin, Wen‐Ying, et al.
Publicado: (2022)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir
por: Polansky, Hanan, et al.
Publicado: (2016)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017)

Camalexin Induces Apoptosis via the ROS-ER Stress-Mitochondrial Apoptosis Pathway in AML Cells
por: Yang, Yang, et al.
Publicado: (2018)

Herpes zoster ophthalmicus or Herpes zoster maxillaris?
por: Chandravanshi, Shivcharan Lal, et al.
Publicado: (2009)

Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
por: Wei, GuoQing, et al.
Publicado: (2017)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
por: Han, Xiaoyan, et al.
Publicado: (2017)

The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2019)

Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models
por: He, Donghua, et al.
Publicado: (2016)

Herpes Zoster
por: Warneros Loyo, María de Lourdes
Publicado: (1995)

Herpes Zoster
Publicado: (1890)

Herpes Zoster
por: Wile, Henry
Publicado: (1886)

A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia
por: Pridgen, William L, et al.
Publicado: (2017)

Disseminated herpes zoster with mucosal involvement in an immunosuppressed child
por: Miao, Chaoyang, et al.
Publicado: (2022)

Evaluation of microRNA Expression in Patients with Herpes Zoster
por: Li, Xihan, et al.
Publicado: (2016)

Herpes Zoster / Revisión Bibliográfica /
por: Escamilla Sánchez, Jacqueline
Publicado: (1993)

Concerns in assessing risk factors for herpes zoster infection in multiple myeloma patients
por: Lee, Dong-Gun
Publicado: (2010)

High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis
por: te Linde, Elsemieke, et al.
Publicado: (2022)

Herpes Zoster Ophthalmicus
por: Catron, Thomas, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_fs33mg46p7djks68lgdles47on